Published in Mov Disord on May 15, 2007
Randomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomes. Neurology (2012) 3.46
A meta-regression of the long-term effects of deep brain stimulation on balance and gait in PD. Neurology (2010) 1.47
Effects of subthalamic stimulation on speech of consecutive patients with Parkinson disease. Neurology (2010) 1.44
Effect of subthalamic stimulation on voice and speech in Parkinson's disease: for the better or worse? Front Neurol (2014) 0.98
Patient-specific model-based investigation of speech intelligibility and movement during deep brain stimulation. Stereotact Funct Neurosurg (2010) 0.97
Mechanisms of deep brain stimulation. J Neurophysiol (2015) 0.93
Selecting deep brain stimulation or infusion therapies in advanced Parkinson's disease: an evidence-based review. J Neurol (2013) 0.90
Effect of deep brain stimulation on speech performance in Parkinson's disease. Parkinsons Dis (2012) 0.86
Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports. J Neurol (2010) 0.85
Low-frequency subthalamic nucleus deep brain stimulation for axial symptoms in advanced Parkinson's disease. J Neurol (2013) 0.83
Reduced levodopa-induced complications after 5 years of subthalamic stimulation in Parkinson's disease: a second honeymoon. J Neurol (2009) 0.80
60-Hz frequency effect on gait in Parkinson's disease with subthalamic nucleus deep brain stimulation. Neuromodulation (2013) 0.78
Deep Brain Stimulation of the Subthalamic Nucleus for Parkinson's Disease in a Patient with HIV Infection: Dual Clinical Benefit. Case Rep Neurol (2011) 0.76
Subthalamic nucleus deep brain stimulation for Parkinson's disease: 8 years of follow-up. Transl Neurodegener (2013) 0.75
My 25 Stimulating Years with DBS in Parkinson's Disease. J Parkinsons Dis (2017) 0.75
Merging DBS with viral vector or stem cell implantation: "hybrid" stereotactic surgery as an evolution in the surgical treatment of Parkinson's disease. Mol Ther Methods Clin Dev (2016) 0.75
The variability of levodopa response in Parkinson's disease: is sensitization reversible? Mov Disord (2008) 0.75
Motor follow-up of parkinsonian patients after deep-brain stimulation. Neurol Sci (2010) 0.75
Deep brain stimulation for treatment-resistant depression. Neuron (2005) 12.39
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord (2008) 9.52
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol (2008) 6.76
Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol (2006) 5.49
Phenomenology and classification of dystonia: a consensus update. Mov Disord (2013) 4.98
Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol (2010) 4.77
From psychogenic movement disorder to functional movement disorder: it's time to change the name. Mov Disord (2013) 4.77
Movement Disorders Society Scientific Issues Committee report: SIC Task Force appraisal of clinical diagnostic criteria for Parkinsonian disorders. Mov Disord (2003) 4.56
Excessive daytime sleepiness and sudden-onset sleep in Parkinson disease: a survey by the Canadian Movement Disorders Group. JAMA (2002) 4.38
Bilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson's disease. Brain (2007) 4.13
Mechanisms of deep brain stimulation. Mov Disord (2002) 3.91
Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord (2007) 3.86
Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress. Proc Natl Acad Sci U S A (2005) 3.83
Mutations in GNAL cause primary torsion dystonia. Nat Genet (2012) 3.66
Corticobasal degeneration and its relationship to progressive supranuclear palsy and frontotemporal dementia. Ann Neurol (2003) 3.22
Subcallosal cingulate deep brain stimulation for treatment-refractory anorexia nervosa: a phase 1 pilot trial. Lancet (2013) 3.21
Dependence of subthalamic nucleus oscillations on movement and dopamine in Parkinson's disease. Brain (2002) 3.15
Potential early markers of Parkinson disease in idiopathic REM sleep behavior disorder. Neurology (2006) 3.10
Criteria for the diagnosis of corticobasal degeneration. Neurology (2013) 3.07
Hemiballism: revisiting a classic disorder. Lancet Neurol (2003) 3.00
Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol (2003) 2.93
Colonic mucosal a-synuclein lacks specificity as a biomarker for Parkinson disease. Neurology (2015) 2.88
Serum urate as a predictor of clinical and radiographic progression in Parkinson disease. Arch Neurol (2008) 2.79
Stereotypies: a critical appraisal and suggestion of a clinically useful definition. Mov Disord (2011) 2.76
Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol (2010) 2.67
A multicentre study on suicide outcomes following subthalamic stimulation for Parkinson's disease. Brain (2008) 2.65
Deep brain stimulation for Parkinson disease: an expert consensus and review of key issues. Arch Neurol (2010) 2.64
A phase I trial of deep brain stimulation of memory circuits in Alzheimer's disease. Ann Neurol (2010) 2.64
Levodopa-carbidopa intestinal gel in advanced Parkinson's disease: final 12-month, open-label results. Mov Disord (2014) 2.64
Mutations in the gene encoding PDGF-B cause brain calcifications in humans and mice. Nat Genet (2013) 2.62
Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord (2006) 2.53
Urate as a predictor of the rate of clinical decline in Parkinson disease. Arch Neurol (2009) 2.46
Memory enhancement induced by hypothalamic/fornix deep brain stimulation. Ann Neurol (2008) 2.46
Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. Am J Psychiatry (2011) 2.46
Deciphering the role of heterozygous mutations in genes associated with parkinsonism. Lancet Neurol (2007) 2.40
MR-guided focused ultrasound thalamotomy for essential tremor: a proof-of-concept study. Lancet Neurol (2013) 2.37
Antidepressant-like effects of medial prefrontal cortex deep brain stimulation in rats. Biol Psychiatry (2010) 2.36
Evidence-based guideline: pharmacologic treatment of chorea in Huntington disease: report of the guideline development subcommittee of the American Academy of Neurology. Neurology (2012) 2.34
Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker. Mov Disord (2013) 2.32
BAG5 inhibits parkin and enhances dopaminergic neuron degeneration. Neuron (2004) 2.29
Early-onset Parkinson's disease caused by a compound heterozygous DJ-1 mutation. Ann Neurol (2003) 2.23
Stimulation of the subthalamic nucleus in Parkinson's disease does not produce striatal dopamine release. Neurosurgery (2003) 2.21
Long-term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease. Mov Disord (2010) 2.20
Severe multivalvular heart disease: a new complication of the ergot derivative dopamine agonists. Mov Disord (2004) 2.19
Large-scale replication and heterogeneity in Parkinson disease genetic loci. Neurology (2012) 2.18
Beta oscillatory activity in the subthalamic nucleus and its relation to dopaminergic response in Parkinson's disease. J Neurophysiol (2006) 2.18
Dopamine transporter imaging is associated with long-term outcomes in Parkinson's disease. Mov Disord (2012) 2.18
Mutations in SLC20A2 are a major cause of familial idiopathic basal ganglia calcification. Neurogenetics (2013) 2.11
The subthalamic nucleus in the context of movement disorders. Brain (2003) 2.10
Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain (2009) 2.05
Highly cited works in neurosurgery. Part II: the citation classics. J Neurosurg (2010) 2.04
Short and long latency afferent inhibition in Parkinson's disease. Brain (2003) 2.02
The FM/AM world is shaping the future of deep brain stimulation. Mov Disord (2014) 2.02
Long-term follow up of bilateral deep brain stimulation of the subthalamic nucleus in patients with advanced Parkinson disease. J Neurosurg (2003) 2.01
Bilateral globus pallidus stimulation for Huntington's disease. Ann Neurol (2004) 2.00
Analysis of the glucocerebrosidase gene in Parkinson's disease. Mov Disord (2005) 1.99
A comparison of the mini mental state exam to the Montreal cognitive assessment in identifying cognitive deficits in Parkinson's disease. Mov Disord (2008) 1.98
Bilateral pallidal stimulation for Wilson's disease. Mov Disord (2013) 1.98
Caffeine for treatment of Parkinson disease: a randomized controlled trial. Neurology (2012) 1.91
Basic algorithms for the programming of deep brain stimulation in Parkinson's disease. Mov Disord (2006) 1.89
Factors associated with dopaminergic drug-related pathological gambling in Parkinson disease. Arch Neurol (2007) 1.86
Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities. Lancet Neurol (2013) 1.82
Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications. JAMA Neurol (2013) 1.81
Psychogenic movement disorders. Curr Opin Neurol (2009) 1.81
Deep brain stimulation of the subcallosal cingulate gyrus for depression: anatomical location of active contacts in clinical responders and a suggested guideline for targeting. J Neurosurg (2009) 1.79
Overview of the extranigral aspects of Parkinson disease. Arch Neurol (2009) 1.79
Stimulation of entorhinal cortex promotes adult neurogenesis and facilitates spatial memory. J Neurosci (2011) 1.79
Chronic anterior thalamus stimulation for intractable epilepsy. Epilepsia (2002) 1.78
Amantadine use associated with impulse control disorders in Parkinson disease in cross-sectional study. Ann Neurol (2010) 1.77
Deep brain stimulation: preoperative issues. Mov Disord (2006) 1.77
Impulse control disorders in Parkinson disease: a multicenter case--control study. Ann Neurol (2011) 1.73
How many parkinsonian patients are suitable candidates for deep brain stimulation of subthalamic nucleus? Results of a questionnaire. Parkinsonism Relat Disord (2007) 1.72
Premotor Parkinson's disease: concepts and definitions. Mov Disord (2012) 1.70
The subcallosal cingulate gyrus in the context of major depression. Biol Psychiatry (2010) 1.70
Caffeine in Parkinson's disease: a pilot open-label, dose-escalation study. Mov Disord (2011) 1.66
Ten-year outcome of subthalamic stimulation in Parkinson disease: a blinded evaluation. Arch Neurol (2011) 1.65